PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-22.03%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-22.30%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-22.29%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-22.29%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Negative OCF growth while GNPX is at 3.71%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-72.45%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22389.18%
Negative 10Y OCF/share CAGR while GNPX stands at 77.75%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
42.89%
5Y OCF/share CAGR at 50-75% of GNPX's 77.75%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
64.68%
3Y OCF/share CAGR at 75-90% of GNPX's 77.75%. Bill Ackman would press for improvements in margin or overhead to catch up.
-7255.64%
Negative 10Y net income/share CAGR while GNPX is at 62.66%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-121.67%
Negative 5Y net income/share CAGR while GNPX is 62.66%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
22.78%
Below 50% of GNPX's 62.66%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
5223.15%
Positive growth while GNPX is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
855.06%
Positive 5Y equity/share CAGR while GNPX is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-50.27%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Asset growth above 1.5x GNPX's 10.07%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
59.08%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
15.66%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
40.35%
SG&A growth well above GNPX's 5.22%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.